The Bronx, NY Clinical Trials Report — July 2026

People in The Bronx should act promptly if they match a study closing soon: 30 recruiting trials are expected to close within the next 90 days, including 9 that accept healthy volunteers. The borough also has 560 recruiting trials across 200 research facilities, giving patients and volunteers a broad set of local options—but enrollment may end before a listed closing date if participant targets are reached.

July brought 7 new trials, down from 11 in May. Two of the new studies accept healthy volunteers, while 46 healthy-volunteer trials are recruiting in The Bronx overall. People without a diagnosed condition should review those opportunities now, especially if they have flexible availability for screening or study visits.

Closing-soon studies cover cancer and other conditions

The largest group of trials approaching their projected closing window concerns solid tumors and adult solid tumors. Other closing-soon categories include ovarian and breast cancer, bleeding, anxiety or depression, chronic kidney disease with iron-deficiency anemia, atrial fibrillation, and chronic subdural hematoma.

• Solid tumor: 2 trials
• Ovarian cancer: 2 trials
• Solid tumor, adult: 2 trials
• Solid tumor, unspecified, adult: 2 trials
• Bleeding, breast cancer, anxiety or depression, chronic kidney disease with iron-deficiency anemia, atrial fibrillation, and chronic subdural hematoma: 1 trial each

Healthy volunteers are eligible for 9 of the closing-soon studies. Eligibility can depend on age, medications, medical history, laboratory results, and the ability to attend required visits. Prospective participants should contact the listed research facility directly rather than waiting for the projected closing date.

Major Phase 3 opportunities opened locally

Three of July’s new trials are drug studies, alongside 2 device studies, 1 behavioral study, and 1 study classified as other. Several openings involve later-stage therapies sponsored by established organizations and may interest people with specific diagnoses.

• NCT07680790, the Phase 3 IZABRIGHT-Lung02 study sponsored by Bristol-Myers Squibb, compares izalontamab brengitecan with osimertinib alone or osimertinib plus platinum-based chemotherapy for previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer. Planned enrollment is 850 participants.
• NCT07711418 is a Phase 3 study sponsored by Nektar Therapeutics evaluating rezpegaldesleukin, also known as NKTR-358, in people aged 12 and older with moderate-to-severe atopic dermatitis. The randomized, double-blind study plans to enroll 510 participants.
• NCT07715877, sponsored by Albert Einstein College of Medicine, examines social media connectedness among people with fibromyalgia. The study lists planned enrollment of 1,041 participants and focuses on how connection through social media may relate to well-being and depressive symptoms.

Other new-trial categories include blood pressure, infant nutrition disorders, infection, osteosarcoma, perfusion index, postnatal care, and premature birth. The July openings also include one non-small cell lung cancer study, adding to local options for people seeking oncology research.

Montefiore sites anchor Bronx research access

Montefiore-affiliated facilities account for the largest concentrations of recruiting studies in The Bronx. Montefiore Medical Center leads with 162 trials, followed by the Moses Campus with 78 and the Einstein Campus with 59. These sites provide access to oncology, pediatric care, cardiovascular research, dermatology, maternal and infant health, and other specialties.

• Montefiore Medical Center: 162 trials
• Montefiore Medical Center - Moses Campus: 78 trials
• Montefiore Medical Center-Einstein Campus: 59 trials
• Montefiore Medical Center-Weiler Hospital: 28 trials
• Research Site: 19 trials
• Children's Hospital at Montefiore: 15 trials
• Albert Einstein College of Medicine: 14 trials
• James J Peters VA Medical Center: 12 trials
• Montefiore Einstein Comprehensive Cancer Center: 12 trials
• Jacobi Medical Center: 11 trials

People considering cancer studies should begin with Montefiore Medical Center, its Einstein-affiliated locations, and Montefiore Einstein Comprehensive Cancer Center. Families seeking pediatric research can check Children's Hospital at Montefiore, while eligible veterans may find opportunities through James J. Peters VA Medical Center locations.

Healthy-volunteer and age eligibility

Of the 7 trials opened in July, 2 accept healthy volunteers. None is restricted exclusively to women or men. Two new studies include children, and 6 include older adults. These figures describe eligibility categories in the new-trial data; each study may apply additional requirements.

Local sponsors include Albert Einstein College of Medicine, Montefiore Medical Center, James J. Peters Veterans Affairs Medical Center, Bristol-Myers Squibb, Nektar Therapeutics, and H. Lee Moffitt Cancer Center and Research Institute. Three new studies are industry-sponsored, three are categorized as other, and one is federally sponsored.

Other New York cities to consider

Participants willing to travel can search beyond The Bronx. New York has 55 recruiting trials in the nearby-city comparison, while Rochester has 10. Buffalo and Commack each have 5, Harrison has 5, Uniondale has 4, Lake Success has 3, and Stony Brook has 2.

The recent trend shows monthly new-trial counts of 14 in February, 8 in March, 10 in April, 11 in May, and 7 in July, with June at 11 and August currently showing 1. As the summer pipeline changes, local patients and healthy volunteers should monitor Montefiore-affiliated sites and contact closing-soon studies early.